Giselle Mosnaim

Jan 9, 2025 | digitalcommons.library.tmc.edu | Moisés Huamán |JAY RAVAL |James Paxton |Giselle Mosnaim

BACKGROUND: COVID-19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS-CoV-2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials. STUDY DESIGN AND METHODS: We analyzed data pertaining to transfusion-related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings.

Aug 6, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

OpinionVideoAugust 6, 2024Author(s):,Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway. Video content above is prompted by the following:A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on certain recommended doses.

Aug 6, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

Aug 6, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

OpinionVideoAugust 6, 2024Author(s):A panel of experts discuss the positives and negatives in using omalizumab when treating patients with CSU. Video content above is prompted by the following:A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on recommended doses of omalizumab. What do you believe accounts for this high number of patients who are not responding adequately? Patients have to come in for first 3 doses because this a biologic.

Jul 29, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

OpinionVideoJuly 29, 2024Author(s):A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU. Video content above is prompted by the following question(s):Which healthcare specialties are involved in managing patients with CSU, and how can multidisciplinary care be optimized? What are the comorbidities that are most seen in patients with CSU, and how do these affect your management plan?